Citicoline (Cdp-Choline) for Cognitive Function

Research suggests that citicoline may support cognitive function and neurological recovery, with one randomized, placebo-controlled trial of 259 acute ischemic stroke patients finding that citicoline-treated groups showed significantly better outcomes across measures of cognitive function, neurological deficit, and functional ability compared to placebo at 12 weeks. The available evidence comes from a single RCT conducted in a specific clinical population, namely patients recovering from acute ischemic stroke, which limits how broadly these findings can be applied to healthy individuals or other cognitive contexts. Studies indicate the compound was generally well-tolerated in this trial, with no drug-related serious adverse events reported. The evidence base here is narrow, and more research across diverse populations and study designs would be needed to draw broader conclusions about citicoline's effects on cognitive function generally.